Gazyva (obinutuzumab)

pCPA File Number: 20806

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0041-000

pCPA Engagement Letter Issued:

2015-02-10

Negotiation Process Concluded:

2015-05-15